Preventing Future Cancers by Testing Women With Ovarian Cancer forBRCAMutations
- 1 February 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (4) , 675-682
Abstract
Purpose: Women with ovarian cancer have a 10% probability of carrying a BRCA mutation. If a mutation is identified, unaffected family members can undergo genetic testing and cancer risk-reducing strategies. We estimated the net health benefits and cost-effectiveness of different criteria for BRCA mutation testing in women with ovarian cancer, and the downstream benefits for their first-degree relatives (FDRs).Methods: We developed a Markov Monte Carlo simulation model to compare four criteria for BRCA testing in women with ovarian cancer: no testing (reference); only if personal history of breast cancer, family history of breast/ovarian cancer, or Ashkenazi Jewish ancestry; only if invasive serous cancer; any invasive nonmucinous epithelial cancer. Net health benefit was life expectancy for FDRs and primary outcome was the incremental cost-effectiveness ratio (ICER). The model estimated the number of future breast and ovarian cancer cases in FDRs.Results: BRCA testing based on personal/family history and ancestry could prevent future cases in FDRs with an ICER of $32,018 per year of life (LY) gained compared with the reference strategy. BRCA testing based on serous or any nonmucinous epithelial ovarian cancer could prevent more cancer cases, but at ICERs of $128,465 and $148,363 per LY gained, respectively.Conclusion: BRCA testing of women with ovarian cancer based on personal/family history of cancer or Ashkenazi Jewish ancestry is a cost-effective strategy to prevent future breast and ovarian cancers among FDRs. More inclusive testing strategies prevent additional cancer cases but at significant cost.Keywords
This publication has 73 references indexed in Scilit:
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective StudyJournal of Clinical Oncology, 2008
- International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriersInternational Journal of Cancer, 2008
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up studyBritish Journal of Cancer, 2007
- Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-upBritish Journal of Cancer, 2007
- Characterization ofBRCA1andBRCA2Mutations in a Large United States SampleJournal of Clinical Oncology, 2006
- Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study GroupJournal of Clinical Oncology, 2004
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesThe American Journal of Human Genetics, 1998